Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/17527
Non-bacterial chronic osteomyelitis: Experience in a tertiary hospital
WOS ID: 000379450100004
Scopus EID: 2-s2.0-84951033675
Embase PUI: L607375335
StatisticsItem usage statistics
MetadataShow Dublin Core item record
Document typeresearch article
CitationBarral Mena E, Freire Gomez X, Enriquez Merayo E, Casado Picon R, Bello Gutierrez P, De Inocencio Arocena J. Non-bacterial chronic osteomyelitis: Experience in a tertiary hospital. An Pediatr. 2016 Jul;85(1):18-25. Epub 2015 Oct 23.
Introduction: Non-bacterial chronic osteomyelitis (NBCO) is an autoinflammatory disease that presents with recurrent bouts of bone inflammation in the absence of microbiological isolation. It is a diagnosis of exclusion. Its treatment was classically based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, although nowadays bisphosphonates or anti tumour necrosis factor-alpha (anti-TNF) drugs are frequently used with good results. The objective of the study is to describe our experience in the diagnosis and treatment of patients with NBCO. Patients and methods: Retrospective chart review of patients with NBCO followed up in a tertiary centre between 2008 and 2015. Results: A total of 7 patients with NBCO were recorded. Four were female and the median age was 10 years (IQR 2). The most common complaint was pain that interfered with sleep in 5 of the patients. Six patients had multifocal lesions at diagnosis. Bone biopsy demonstrated neutrophilic or lymphocytic infiltration and sclerosis in 6 patients. Four patients received antibiotics and NSAIDs without clinical response. Five received a short course of prednisone with an adequate control of symptoms, but only one of them maintained remission after corticosteroid suspension. Five patients received bisphosphonates with disease remission in 3 of them. The other 2 showed an inadequate response to pamidronate and were started on anti-TNF therapy (etanercept, intliximab or adalimumab), remaining asymptomatic at present. Conclusions: Our-series, although limited, confirms the effectiveness and safety of bisphosphonate and anti-TNF therapy for children with NBCO.
Centros de Atención Terciaria